🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Optime Care to manage GAVRETO patient support

EditorBrando Bricchi
Published 06/27/2024, 02:32 PM
RIGL
-

ST. LOUIS - Optime Care, a specialty pharmacy and part of AscellaHealth, has announced a new partnership with Rigel (NASDAQ:RIGL) Pharmaceuticals to provide patient support services for GAVRETO® (pralsetinib) starting July 1, 2024. GAVRETO® is an oral therapy for the treatment of certain cancers with abnormal RET genes.

The partnership aims to utilize Optime Care's expertise in handling specialized, complex diseases. Their services include medication fulfillment, patient intake, prescription authorization, reimbursement assistance, and financial aid programs. These integrated patient management and HUB services are designed to enhance patient outcomes and ensure seamless treatment experiences.

Stephanie Wasilewski, PharmD, General Manager at Optime Care, expressed enthusiasm about expanding their collaboration with Rigel Pharmaceuticals . She emphasized the company's commitment to personalized care and the optimization of therapeutic outcomes for patients on their treatment journey.

Rigel Pharmaceuticals, known for its work in small molecule drug development for various disorders, selected Optime Care for their proven expertise and dedication to patient care. Scott Yohe, VP of market access at Rigel, highlighted the importance of comprehensive services to improve therapeutic outcomes for patients affected by cancers caused by abnormal RET genes.

GAVRETO® has been prescribed for adults with non-small cell lung cancer that has spread and for adults and children 12 years and older with advanced or metastatic thyroid cancer after radioactive iodine treatment has failed. The FDA has approved GAVRETO® based on patient response rates and the duration of those responses, with ongoing studies to confirm the benefits.

Optime Care holds dual-accreditation from URAC and ACHC, showcasing its commitment to quality care in treating orphan and rare disorders. The partnership with Rigel Pharmaceuticals is set to begin in July, aiming to support patients and enhance access to GAVRETO®.

This collaboration is based on a press release statement and does not include any endorsements of claims. The information provided is intended for educational purposes only and does not constitute medical advice.

In other recent news, Rigel Pharmaceuticals has announced several significant developments. The company has implemented a 1-for-10 reverse stock split, aiming to improve its stock's marketability and meet Nasdaq's minimum bid price requirement for continued listing. In terms of product releases, Rigel is set to offer GAVRETO, a medication for specific types of cancer, following full FDA approval for non-small cell lung cancer and accelerated approval for advanced thyroid cancer.

In the financial realm, Rigel reported net product sales of $21.1 million for TAVALISSE and $4.9 million for REZLIDHIA in the first quarter of 2024. Despite a 5% decrease in net product sales for TAVALISSE compared to the same period in 2023, CEO Raul Rodriguez remains confident in the growth trajectory of both products. The company ended the quarter with $49.6 million in cash, cash equivalents, and short-term investments.

In addition to these developments, Rigel completed the acquisition of GAVRETO from Blueprint Medicines (NASDAQ:BPMC) Corporation in February 2024, aiming to expand its hematology and oncology business. The company is also in pursuit of additional in-licensing deals and acquisitions to further expand its portfolio. These are among the recent developments as Rigel continues to focus on product expansion and market positioning in the oncology sector.

InvestingPro Insights

As Optime Care embarks on its new partnership with Rigel Pharmaceuticals, investors and stakeholders of Rigel are closely monitoring the company's financial health and market performance. According to real-time data from InvestingPro, Rigel Pharmaceuticals currently holds a market capitalization of $138.73 million. Despite the potential for growth through strategic partnerships, such as the one with Optime Care, Rigel's financial data reflects some challenges. The company has not been profitable over the last twelve months, with a reported revenue decline of 4.66%. However, there is a silver lining with a quarterly revenue growth of 13.29%, indicating some positive momentum in the company's earnings.

InvestingPro Tips suggest that Rigel's stock may be in oversold territory, as indicated by the RSI, and has taken significant hits over the past week, three months, and six months. Analysts are not expecting the company to be profitable this year, which is consistent with the negative P/E ratio of -6.9. Additionally, the stock is trading at a price that is 45.66% of its 52-week high, reflecting the recent downturn in its market valuation.

For those interested in gaining more insights and tips on Rigel Pharmaceuticals, additional information is available on InvestingPro. Subscribers can access a wealth of data and analysis to make informed decisions. To enrich your investment strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With more than 6 additional InvestingPro Tips available, investors can better navigate the complexities of the market and the implications of Rigel's partnership with Optime Care.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.